# Capecitabine in ER+/HER2-negative Breast Cancer

> **NCT07631052** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 15 (estimated)

## Conditions studied

- ER-positive, HER2-negative Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Breast Cancer Stage III

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT07631052
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2029-08-01
- **Final completion:** 2029-08-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631052, "Capecitabine in ER+/HER2-negative Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*